



COUNCIL FOR AFFORDABLE  
**HEALTH COVERAGE**

May 21, 2026

Dear Members of the Senate,

On behalf of the Council for Affordable Health Coverage (CAHC), we urge you to oppose the inclusion of any “Most Favored Nation” (MFN) or policies that institute government price controls on prescription medicines in the upcoming reconciliation package and during vote-a-rama consideration.

CAHC strongly supports policies that lower costs and improve affordability for Americans. However, MFN policies would import foreign government price controls into the United States’ healthcare system, threatening the innovation, access, jobs, and market-based competition patients rely on.

Americans already face rising health costs and affordability challenges. Policymakers should focus on solutions that strengthen access to coverage and care, encourage competition, and support medical innovation, rather than policies that disrupt access to life-saving therapies and undermine the development of future treatments.

MFN proposals tie U.S. drug prices to those set by foreign governments, which frequently restrict patient access to medicines, delay availability of new therapies, and underinvest in biomedical innovation. These systems achieve lower prices through centralized government controls and utilization restrictions that are fundamentally inconsistent with the patient-centered, innovation-driven framework that made the U.S. the global leader in developing new cures and treatments.


Implementing MFN policies through reconciliation would have serious unintended consequences across the health care system, including:

- Reduced patient access to physician-administered drugs and innovative treatments
- Financial instability for physician practices and outpatient providers, particularly in rural and underserved communities
- Stifling the creation of state-of-the-art manufacturing facilities
- Increased barriers to care for patients with chronic, rare, and complex conditions
- Reduced incentives for the research and development of future cures

CAHC remains committed to advancing practical, market-based reforms that improve affordability and expand access without sacrificing innovation or patient choice. We respectfully urge you to oppose the inclusion of MFN drug pricing provisions in the reconciliation package and reject any related amendments during vote-a-rama.

Thank you for your consideration and continued leadership on policies that improve affordability and protect patient access to high-quality care.

Sincerely,



Joel C. White  
President